Zacks Research Issues Optimistic Outlook for Sanofi Earnings

Sanofi (NASDAQ:SNY) – Investment analysts at Zacks Research lifted their Q1 2025 EPS estimates for Sanofi in a research note issued to investors on Wednesday, January 22nd. Zacks Research analyst K. Shah now expects that the company will post earnings of $0.85 per share for the quarter, up from their previous estimate of $0.84. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Zacks Research also issued estimates for Sanofi’s Q2 2025 earnings at $0.94 EPS, Q4 2025 earnings at $1.10 EPS, FY2025 earnings at $4.47 EPS and Q3 2026 earnings at $1.47 EPS.

Separately, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $53.34 on Monday. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a market cap of $135.37 billion, a PE ratio of 27.21, a P/E/G ratio of 1.19 and a beta of 0.57. The stock has a 50 day simple moving average of $48.80 and a 200-day simple moving average of $52.21.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.55 EPS.

Institutional Trading of Sanofi

Several institutional investors and hedge funds have recently added to or reduced their stakes in SNY. Dimensional Fund Advisors LP lifted its holdings in shares of Sanofi by 0.4% during the second quarter. Dimensional Fund Advisors LP now owns 318,760 shares of the company’s stock valued at $15,466,000 after purchasing an additional 1,238 shares during the last quarter. AQR Capital Management LLC purchased a new stake in shares of Sanofi in the 2nd quarter valued at approximately $344,000. The Manufacturers Life Insurance Company boosted its stake in Sanofi by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,528 shares of the company’s stock worth $1,530,000 after purchasing an additional 6,756 shares during the period. Creative Planning raised its stake in Sanofi by 9.2% during the 2nd quarter. Creative Planning now owns 187,035 shares of the company’s stock valued at $9,075,000 after purchasing an additional 15,749 shares during the period. Finally, NewEdge Advisors LLC boosted its position in shares of Sanofi by 27.2% in the second quarter. NewEdge Advisors LLC now owns 29,587 shares of the company’s stock worth $1,436,000 after buying an additional 6,330 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.